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REEVALUATING FECAL MICROBIOTA TRANSPLANTATION FOR 
RECURRENT CLOSTRIDIUM DIFFICILE INFECTION 
MARIAH HAMILTON 
ABSTRACT 
Clostridium difficile infection (CDI) is a disease associated with the wide-spread use of 
antibiotics and causes 450,000 infections and almost 30,000 deaths in the United States 
annually. Recurrence is a major problem, with approximately 1/3rd of patients relapsing 
after antibiotic treatment for CDI. Fecal Microbiota Transplantation (FMT) has emerged 
as a novel therapy for recurrent CDI, but the majority of the literature to date is made up 
of uncontrolled case series, so FMT’s true efficacy compared with standard antibiotic 
regimens remains unknown. Only a few randomized control trials (RCTs) have been 
published, and these have studied small numbers of patients and exhibited marked 
methodological heterogeneity. As such, there is uncertainty about the appropriate 
indications for FMT with respect to recurrent CDI, as well as the best methodology for 
the procedure, which has been carried our using various fecal preparations and modes of 
delivery. In particular, questions remain about if FMT should be recommended for 
patients with a first CDI recurrence, and if minimally invasive methods of performing 
FMT such as administration of enteric coated capsules are more efficacious than standard 
antibiotic treatments. We propose a double blind, placebo controlled, RCT that will be 
run as two parallel RCTs, where Trial 1 will enroll patients experiencing a first CDI 
recurrence, and Trial 2 will enroll patients experiencing a second or later CDI recurrence. 
The treatment arms in each trial will receive FMT in the form of orally administered 
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frozen capsules, while the control arms will receive standard antibiotic treatments based 
on the number of recurrences they have experienced. If shown to be efficacious in a large 
RCT, oral capsulized FMT alone as treatment for recurrent CDI has the potential to 
increase access to FMT, decrease unnecessary antibiotic use, and substantially reduce 
morbidity and mortality attributable to CDI. 
. 
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INTRODUCTION 
Background 
Since the first usage of penicillin on humans in the early 1940s, antibiotics have 
been the mainstay of treatment for bacterial infections. As a result, many bacterial 
diseases that previously were life-threatening are nearly always treatable and seldom 
produce significant morbidity. Despite the undeniable benefit of these agents in treatment 
bacterial infections, the widespread use of broad spectrum antibiotics has not been 
without costs. Arguably the most impactful and best-characterized of these costs has been 
the evolution of antimicrobial resistance among many prominent human pathogens, 
giving rise to bacterial strains such is methicillin-resistant S. aureus, vancomycin-
resistant Enterococcus, and multi-drug resistant tuberculosis.  
However, emerging bacterial resistance is not the only mechanism by which the 
widespread use of broad spectrum antimicrobial agents has exerted harm on human 
populations; Clostridium difficile infection (CDI) is another prominent example. The 
pathophysiology of CDI has been well-characterized, and involves changes to the 
bacterial diversity of the normal gut flora after the use of a broad spectrum antibiotic, 
creating an environment that is more permissive to the vegetation of C. difficile spores, 
which become metabolically active and secrete exotoxins that can cause a range of illness 
from mild diarrhea to pseudomembranous colitis and death1. In recent decades, CDI has 
emerged as one of the most common and important healthcare-associated infections in 
the developed world, with 450,000 cases and almost 30,000 deaths in the US annually2.  
Management of CDI includes stopping all antibiotics that the patient is taking as soon as 
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possible, instituting infection control policies, correcting fluid losses and electrolyte 
imbalances and starting antibiotics specific for CDI.  While there are several 
antimicrobial options for the treatment of CDI, they are frequently ineffective at 
producing a durable cure, and approximately 20-30%  of patients treated for their first 
episode of CDI with antibiotics experience a recurrence3, a pattern of disease for which 
continued gut dysbiosis in the face of continued antimicrobial exposure is thought to be 
responsible.  Even more concerning, second and later recurrences of CDI carry a 50-65% 
risk of relapse4. 
Given this overall poor response of recurrent CDI to conventional antimicrobial 
therapies, novel treatments including fecal microbiota transplantation (FMT) have been 
explored more intensively in recent years. The goal of FMT is to increase the patient’s 
intestinal microbial diversity using stool from a healthy donor in order to reverse the 
colonic environment that allows C. difficile to become metabolically active and cause 
disease. FMT has emerged as a potentially promising treatment for recurrent CDI, 
however, the literature to date is unclear about the indication and contraindications for 
FMT in recurrent CDI and the best way to perform the procedure, including donor testing 
and patient preparation for the procedure.    
 
Statement of the Problem 
Dozens of uncontrolled clinical trials have examined FMT for recurrent CDI, however, 
there have been few high-quality randomized controlled trials (RCTs).  The RCTs that 
have been conducted have studied a small number of patients and have not followed 
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standard guidelines for quality5.  Despite the lack of high-quality evidence supporting the 
use of FMT as an effective treatment for recurrent CDI, initial results have been 
promising and clearly support further research. Many clinicians and medical centers have 
adopted their own approach to FMT for patients with multiple recurrences of CDI.  
Given the potential for benefit of FMT in recurrent CDI, a high-quality RCT to 
determine its efficacy in a well-defined at risk population is necessary. Following that, 
future investigation could identify comorbidities that should be considered 
contraindications to FMT therapy, establish if FMT has benefit compared with antibiotics 
on the first CDI recurrence, explore whether there is a benefit or detriment to pre-FMT 
anti-CDI antimicrobial therapy, and define the optimal preparation of donor stool and 
route of administration with respect to ease of administration, risk, and efficacy. It is 
likely that multiple, large-scale RCTs will be needed to characterize all of these 
parameters in a satisfactory manner.  The objectives of the study proposed here will be to 
evaluate FMT therapy for the indication of recurrent CDI compared with standard 
antibiotic regimens within two distinct subgroups of recurrent CDI, namely first 
recurrence and second or later recurrence.   
 
Hypothesis 
We propose to conduct two parallel clinical trials to evaluate the efficacy of FMT 
administered as a single dose of frozen capsules taken orally among patients experiencing 
either a first recurrence of CDI (Trial 1) versus a second or later recurrence (Trial 2) 
compared with the standard antibiotic treatment for initial and subsequent recurrences. 
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The trials will operate in tandem utilizing the same staff, and will differ only with respect 
to two factors: the inclusion criterion of first CDI recurrence versus later recurrence, and 
the treatment received within the control arms of each trial. This approach is necessary in 
order to ensure an adequately powered analysis of the efficacy of FMT to treat first 
recurrences of CDI, and also because the recommended antibiotic regimens to treat first 
recurrences versus later recurrences are different. We hypothesize that frozen, capsulized 
stool from unrelated pre-screened donors administered orally upon diagnosis of 
symptomatic, laboratory-confirmed CDI (initial or subsequent recurrences) will have a 
clinically significantly lower treatment failure rate over a 12 week follow up period than 
either a 14-day course of oral vancomycin or a 6-week vancomycin taper, among patients 
experiencing a first recurrence of CDI or a second or later recurrence of CDI, 
respectively.  
 
Objective and specific aims 
CDI is a serious public health problem in the developed world, causing substantial 
morbidity and mortality in the United States. The poor performance of antibiotics in 
preventing recurrence of CDI highlights that it is primarily a disease of gut dysbiosis 
brought about by over-reliance on the use of broad-spectrum antibiotics. Therefore, it is 
essential to investigate novel, non-antimicrobial therapies as a solution to the problem of 
recurrent CDI with FMT emerging as a promising candidate. Yet, much of the current 
literature arrived at unfounded conclusions about FMT for recurrent CDI, stating that it 
has been shown to be safe and efficacious, when in fact the literature to date is 
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insufficient to rigorously support this claim. The objective of the present work is to 
describe the current body of literature on FMT as a treatment for recurrent CDI with 
analysis of its strengths and weaknesses, and particular attention to gaps in knowledge 
that are important for guiding clinical decision-making. We will then propose a 
methodology for a double-blind RCT designed to address several of these current 
knowledge gaps.  
The specific aims are: 
• Demonstrate that clinically significant uncertainties exist surrounding the true 
efficacy, indications, contraindications, and optimal methodology for FMT as a 
treatment for recurrent CDI, which have not been adequately addressed by the 
present literature 
• Propose a methodology for a double-blind RCT that addresses several of the most 
clinically impactful outstanding questions about FMT for recurrent CDI 
• Outline likely limitations of the proposed study and suggest areas for future 
research 
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REVIEW OF THE LITERATURE 
Overview 
Epidemiology of Clostridium difficile infection 
Clostridium difficile is a gram positive, spore-forming rod that colonizes the colon of 
some individuals and, when permissive environmental conditions are met, becomes 
metabolically active and secretes toxins that cause enterocyte necrosis, localized 
inflammation, diarrhea, and pseudomembranous colitis1. First recognized as the agent of 
disease in a group of patients in 19786, Clostridium difficile infection (CDI), is now the 
most common cause of health-care associated infections in the United States,7 as well as 
the leading cause of gastroenteritis-related deaths8. The results of a Centers for Disease 
Control and Prevention active surveillance project at ten sites within the United States 
estimated the annual incidence of CDI to be over 450,000 with 29,000 deaths in 20112. 
Incidence is increasing with discharge data from community hospitals demonstrating a 
near doubling of new CDI cases between 2001 and 2010. The estimated economic burden 
is substantial; a recent systematic review estimated the attributable cost per hospitalized 
patient due to CDI to be between $8,911 and $30,0499.  
 
Risk factors  
The major risk factors that have been identified for CDI are antecedent antimicrobial 
exposure, hospitalization, residence in a long term care facility (LTCF), and age >6510. 
Other probable risk factors include use of proton pump inhibitors, multiple comorbidities, 
immunocompromised state, and inflammatory bowel disease10. While CDI was long 
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viewed as a disease affecting primarily hospitalized and healthcare-exposed patients, it 
has been recently recognized that community acquired cases represent a significant and 
epidemiologically distinct group of cases and that recent antibiotic exposure is not always 
present11. Still, antimicrobial exposure remains the most important risk factor for CDI 
and, thus, CDI as a public health problem is a strong impetus for increasing and 
improving antimicrobial stewardship. While clindamycin was the first antibiotic 
identified in connection with CDI, nearly all classes of antibiotics carry some risk. The 
following antibiotics and classes have all been linked to CDI (odds ratios from a 2013 
meta-analysis):  clindamycin (OR 20.4), fluoroquinolones (OR 5.7), cephalosporins (OR 
4.5), penicillins (OR 3.3), macrolides (OR 2.6), and Bactrim (OR 1.8)12. It is important to 
note that these are commonly prescribed antibiotics. For example clindamycin is used to 
treat middle ear infections caused by penicillin-resistant bacteria, and fluoroquinolones 
and cephalosporins are mainstays of treatment of a broad array of common bacterial 
infections, including respiratory infections, gastrointestinal infections, skin infections, 
and urinary tract infections.Tetracyclines, commonly used to treat acne and tick-borne 
infections, have not been linked to CDI12.  
 
Clinical presentation  
CDI is characterized clinically by diarrhea (defined as at least 3 unformed stools in a 24-
hour period or at least 8 unformed stools in a 48-hour period), abdominal pain, 
leukocytosis, reduced renal function, low-grade fever, and in some cases 
pseudomembranous colitis, an accumulation of dead enterocytes and neutrophils in the 
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colon creating the appearance of pseudomembranes10. Diarrhea may contain mucous or 
occult blood but frank melena (black, tarry stools, usually indicative of an upper GI 
bleed) and hematochezia (maroon or bright red blood in the stools, often indicative of a 
lower GI bleed) are uncommon13. In more severe forms of the disease, diarrhea may be 
absent due to the presence of an ileus, a functional bowel obstruction caused by a failure 
of peristalsis. Pseudomembranous colitis is pathognomonic of CDI but is only present in 
a subset of cases and is diagnosed by visualizing pseudomembranes on colonoscopy. 
Important sequelae of CDI include toxic mega colon, sepsis, and death. A standardized 
framework for risk stratification by disease severity exists with different treatment 
algorithms for each stratum (see Treatment section below). The defined levels of disease 
severity are mild/moderate, severe, and severe complicated. Mild to moderate disease is 
characterized by white blood cell (WBC) count less than 15,000 and serum creatinine less 
than 1.5 times baseline, while severe disease criteria are met when one of these values is 
exceeded. Severe complicated disease occurs when hypotension, shock, ileus, or 
megacolon are present.  Recurrence is a significant challenge in management of CDI 
patients and will be discussed in the Prognosis section, below. 
 
Pathophysiology  
The pathophysiology of CDI is tightly linked to the bacterium’s ability to form spores 
and innately resist eradication by most classes of antibiotics. When conditions are 
permissive, these spores vegetate in the anoxic environment of the colon and produce two 
cytotoxins, A and B. Although C. difficile is an obligate anaerobe, the spores survive well 
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in aerobic environments. They are also resistant to heat and alcohol-based hand 
sanitizers, necessitating specialized hand washing and room cleaning protocols in 
hospitals and long term care facilities to prevent their spread1. Vegetation of the spores 
occurs only in the lower colon, a near-anoxic environment, and is supported by bile 
acids1. More specifically, primary bile acids appear to create conditions favorable for 
vegetation of the spores, while secondary bile acids favor spore formation and prevent 
vegetation. Because certain commensal bacteria are producers of secondary bile acids, it 
has been hypothesized that this is one mechanism through which decreased bacterial 
diversity in the colon may lead to increased risk of CDI. Once spores enter a vegetative 
state and become metabolically active, they secrete the exotoxins (Tox A and Tox B) in 
response to poor nutrient levels. These toxins have a cytopathic effect on enterocytes, 
which activates the inflammatory response1. Studies in which hamsters were infected 
with gene deletion C. difficile mutants have been conducted in an attempt to determine 
the pathogenicity contributions of the two toxins individually. C. difficile mutants that 
retained Tox B only, but not Tox A only, were virulent, suggesting that Tox B is a more 
important virulence factor than Tox A14. There is considerable genetic heterogeneity 
among strains of C. difficile, and one strain in particular, NAP1 (North American pulse 
field gel electrophoresis type 1), has been observed to produce more severe disease in 
epidemiologic studies. In addition to Tox A and B, the NAP1 strain also produces a 
binary toxin, which has activity that has not been fully characterized, but is hypothesized 
to be responsible for the increased virulence of this strain that has been observed15.  
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Diagnosis  
Diagnosis of CDI should be made based on clinical suspicion combined with appropriate 
laboratory testing. In general, patients should be considered for laboratory testing if they 
have diarrhea and one or more risk factors (e.g. recent hospitalization, recent antibiotic 
use) or diarrhea that cannot be explained by another diagnosis13. Laboratory testing 
should consist of a high sensitivity screening test such as toxin gene PCR, followed by a 
high specificity confirmatory test such as toxin enzyme immunoassay (EIA) if the 
screening test is positive16. There are non-negligible rates of asymptomatic carriage of C. 
difficile in the general population (1-3% of healthy people)10, so it is important to note 
that PCR detection of genetic material encoding the toxin genes does not mean that the 
toxin is being presently elaborated. Therefore, a positive C. difficile PCR in a patient with 
diarrhea is only meaningful if other common or likely causes of diarrhea have been ruled 
out, or if it has been followed up by a positive toxin EIA.16  
 
Treatment  
Effective treatment of CDI involves stopping the inciting antibiotic, if one is identified 
and the patient is still taking it, as studies have shown that initiating anti-C. difficile 
antibiotics while continuing the offending antibiotic prolongs diarrhea and makes cure 
less likely to be durable17. If antibiotics must be continued, they should be switched to a 
narrow spectrum agent, if possible. Several antibiotics are available to treat CDI: oral or 
intravenous metronidazole, oral vancomycin, and oral fidaxomicin. Intravenous 
vancomycin is poorly absorbed by the colon and is not an effective treatment for CDI. 
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Current recommendations are oral metronidazole for 10-14 days for mild to moderate 
disease, oral vancomycin for 10-14 days for severe disease, and oral vancomycin plus 
intravenous metronidazole for severe-complicated disease13. The treatment recommended 
by the Infectious Disease Society of America (IDSA) for a first recurrence is vancomycin 
for 10-14 days, while treatment for second or further recurrence should be a vancomycin 
taper or pulsed regimen (see Table 1)13. These recommendations differ from those given 
by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), 
which recommend vancomycin or 10 days of fidaxomicin for a first recurrence of CDI, 
and fidaxomicin exclusively for second or later recurrences18. While vancomycin and 
fidaxomicin are associated with similar initial cure rates, fidaxomicin is better at 
preventing recurrence17. Fecal microbiota transplantation (see FMT Overview section 
below) remains an experimental therapy for CDI at this time and is not expressly 
recommended in point-of-care treatment algorithms. 
Table 1: IDSA Treatment Recommendations for Clostridium difficile Infection 
Initial 
Episode 
Clinical 
Characteristics 
Recommended First-
Line Therapy Duration 
Mild or 
moderate 
Leukocytosis with a 
white blood cell count ≤ 
15,000 cells/mcL AND 
Serum creatinine level 
< 1.5 times premorbid 
level 
Metronidazole 500 mg 
orally 3 times daily 10-14 days 
Severe 
Leukocytosis with a 
white blood cell count ≥ 
15,000 cells/mcL OR 
Serum creatinine level 
≥ 1.5 times premorbid 
level 
Vancomycin 125 mg 
orally 4 times daily 10-14 days 
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Initial 
Episode 
Clinical 
Characteristics 
Recommended First-
Line Therapy Duration 
Severe, 
complicated 
Hypotension or shock 
Ileus 
Megacolon 
Vancomycin 500 mg 
orally or by nasogastric 
tube 4 times daily 
PLUS 
Metronidazole 500 mg 
IV every 8 hours 
Consider rectal 
instillation of 
vancomycin if complete 
ileus 
Stop oral or rectal 
antimicrobial therapy if 
colonic perforation 
demonstrated or 
colectomy imminent 
First 
recurrence 
May be any clinical 
severity 
Treatment is the same as for initial recurrence, 
based on disease severity 
Second or 
later 
recurrence 
May be any clinical 
severity 
Vancomycin 125 mg 4 times daily for 10-14 days, 
then 125 mg twice daily for 1 week, then 125 mg 
once daily for 1 week, then 125 mg/day every 2-3 
days for 2-8 weeks 
 
Table adapted from IDSA guidelines13 
Prognosis 
In the inpatient setting, CDI is associated with longer hospital stays and increased 
mortality in both medical floor and ICU patients19,20. Strikingly, among patients who 
require emergency surgery (most often colectomy) for treatment of complications 
including toxic mega colon, the in-hospital mortality rate is 42%21. Among patients who 
recover fully, clinical course is still fairly likely to be complicated by recurrence with up 
to 30% of patients having a recurrence after their initial CDI episode and up to 65% 
suffering recurrence after a second episode4,22. Risk factors for recurrence that have been 
characterized include age >65, antibiotic exposure after CDI treatment, proton pump 
inhibitor (PPI) use after CDI treatment, and renal insufficiency3. 
As described above, the treatment recommended for recurrent CDI by the IDSA is 
vancomycin, whereas the ESCMID recommends fidaxomicin. However, a number of 
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novel non-antimicrobial therapies are currently under investigation. In addition to FMT, 
these include monoclonal antibodies and stool substitute transplant therapies made from 
purified intestinal bacterial cultures from healthy donors. Stool substitute therapies are 
still in the nascent stages of development, but carry the potential advantage of reduced 
risk of transmission of infectious diseases from FMT23. Monoclonal antibodies have been 
better-studied. For example, bezlotoxumab is a humanized monocloncal antibody that 
binds C. difficile toxin B and has been shown to be safe and effective at preventing CDI 
recurrence in Phase III clinical trials24. However, the these agents are extremely 
expensive, which limits their use. FMT remains a promising and potentially cost-
effective treatment option for recurrent CDI.  
 
FMT overview 
The goal of FMT is to increase microbial diversity through the introduction of whole 
stool from a healthy donor25. Although the first FMT was performed in 1958 for 
pseudomembranous colitis26, no standard protocol for the FMT procedure yet exists, so 
there remains considerable variability of opinion in the medical community about donor 
selection and screening, preparation of donated material, peri-FMT medications, and 
route of administration25. For example, routes of administration that have been used for 
FMT include oral, acid-resistant capsules, nasoduodenal tube, upper endoscopy, 
colonoscopy, flexible sigmoidoscopy, and retention enema27–34. Thus, FMT at this point 
in time is not a single procedure, but many. Of note, FMT in its myriad forms appears to 
be well-tolerated25; the most commonly reported adverse events, according to one meta-
analysis, were cramping, bloating, and diarrhea on the day of the procedure, and serious 
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adverse events were rare and associated with the mode of delivery (such as colonic 
perforation during colonoscopy) rather than the FMT itself .35 Potential indications for 
FMT represent an extremely active area of research and include FMT as a treatment for 
inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome and obesity, 
autoimmune diseases, and cardiovascular diseases25. FMT has even been explored as a 
treatment for behavioral symptoms of autism36. None of these potential indications has 
been studied as much as recurrent CDI, which remains the best-accepted indication for 
FMT. 
 
Existing Research         
Overview  
This review will evaluate the current body of literature that explores the efficacy of FMT 
for CDI with a focus on recurrent CDI. Although recurrent CDI is by far the best-studied 
indication for FMT, many questions remain. The current literature can be divided into the 
following categories: uncontrolled case series, the majority of published clinical studies; 
randomized controlled trials that compare FMT for recurrent CDI to other treatments not 
involving heterologous FMT, of which there are a paucity; randomized controlled trials 
comparing one method of heterologous FMT to another; and myriad systematic reviews, 
meta analyses, and perspective pieces that analyze the results of the case series and 
RCTs. While there is compelling data suggesting that FMT for the indication of recurrent 
CDI is effective, the evidence base is uncertain about how effective it is compared with 
the current standard treatment, as only a few randomized controlled trials have been 
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conducted and they have generally been small. Many reviews have been published in an 
effort to synthesize and make clinical recommendations based on the results of these 
clinical trials and case series, however, they differ in their conclusions; some state that 
FMT is clearly an effective and safe therapy for specific CDI indications while others 
state that more research is needed to establish efficacy and safety. Some reviews have 
stated conclusions that are not supported by the literature, often extrapolating outside 
what can be known from the results of uncontrolled case series or by attributing 
significance to results that were not statistically so. Importantly, there is general 
consensus that additional research is needed to elucidate the optimal procedural details 
for FMT including donor selection, specimen dose and handling, route of administration, 
and timing of peri-FMT medications, such as pre-FMT vancomycin treatment. 
Additionally, little is currently understood about the efficacy of FMT for CDI indications 
other than for multiply recurrent CDI, although some studies suggest that it may be an 
effective salvage therapy for severe complicated CDI and refractory CDI.  More research 
is also needed to understand the mechanism by which FMT exerts its therapeutic effect. 
Some studies have compared the microbiome of donors and patients or have compared 
the microbiome of the patients before and after FMT, and have often demonstrated 
increased bacterial diversity or increases in bacterial species that were prevalent in the 
donor’s microbiome in patients after FMT XXX. Still, these analyses have often been 
performed with convenience samples or subsets of trial participants, so it is likely that 
more studies that include microbiome analysis with larger patient numbers would lead to 
a clearer understanding of the mechanism of FMT and would benefit the development of 
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novel, non-whole stool therapies. Finally, some systematic reviews and meta analyses 
have identified poor standardization of reporting of methodological details within the 
current body of literature. As there is considerable heterogeneity in opinion as to what 
has been firmly established by the current literature and what still needs to be clarified by 
further study, questions about the optimal direction of future research remain. The present 
review will first summarize the case series and two groups of randomized controlled 
trials that have been published to date and will then explore key reviews and meta 
analyses that have attempted to summarize their results with respect to key clinical 
research questions, including estimating the overall efficacy of FMT compared with 
standard treatments, optimizing stool specimen handling and route of administration, and 
characterizing adverse effects of FMT. Lastly, key limitations of existing research and 
conclusions drawn from it will be summarized, and future directions suggested. 
 
Case series  
Case series and case studies have, to date, made up the bulk of published clinical work 
examining the efficacy of FMT for the treatment of recurrent CDI. In their 2017 
systematic review with meta-analysis, Quraishi et al found 175 case series and case 
reports on this topic, including 62 case series published as abstracts, 83 that had a sample 
size less than 10, and 30 that included at least 10 patients37. In addition to the 30 case 
series studies that included at least 10 subjects, Quraishi at el found and included 7 
randomized controlled trials in their meta-analysis (see below subsections for detailed 
descriptions of these studies), and estimated an overall efficacy rate of 92% for FMT to 
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cure recurrent CDI. An overall efficacy rate for the case series alone was not reported, 
although it was stated that cure rates ranged from 68% to 100%. Importantly, the authors 
noted considerable heterogeneity in terms of defined outcomes in the studies, so the 
meta-analysis findings represent a cure rate from studies that ranged in follow up time 
from several weeks to many months. Among the case series, most used fresh stool rather 
than frozen stool for FMT, and lower GI route delivery was more common than upper GI 
delivery. Additional sources of variability among studies included choice of stool solvent 
(most commonly saline, but water and glycerol were also used), amount of stool 
administered (this was extremely variable, with a range of 6 grams to 152 grams), 
premedication regimens (e.g. use of proton pump inhibitors prior to endoscopy, use of 
anti-diarrheal medications to help retain FMT products after lower GI administration, 
timing of cessation of pre-FMT antibiotics), and number of FMT infusions 
administered37. Given the lack of a control group and the extreme variability among these 
case series, it is reasonable to conclude that they do not contribute to a robust evidence 
base. 
 
Randomized controlled trials comparing heterologous FMT to antibiotics or autologous 
FMT  
To date, only 4 randomized controlled trials looking at FMT for recurrent CDI in which 
the control arm did not receive heterologous FMT have been conducted where results 
were published as a full journal article (abstract only results and poster presentations 
were excluded). Trials were identified through systematic searches of PubMed and 
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clinicaltrials.gov using search terms for “fecal microbiota transplantation” and 
“Clostridium difficile infection”, and by cross referencing these lists with the references 
from major systematic reviews and meta-analyses published in 2017. All RCTs meeting 
these criteria were published between 2013 and 2017. The largest trial enrolled a total of 
46 patients across 2 centers; this was also the only trial that was placebo controlled. The 
trials exhibited marked variability with respect to hypothesis, methodology, and 
outcomes being measured (see Table 1). In particular, these studies differed with respect 
to number of recurrent episodes of CDI needed to meet inclusion criteria, dose and 
duration of pre-FMT antibiotic treatments, and follow-up period for the primary 
endpoint. Summaries of these 4 RCTs and their findings are presented in chronological 
order below. 
 
Table 2: Methodological differences between RCTs evaluating FMT compared with 
antibiotics or placebo for recurrent CDI 
 Van Nood (2013) Cammarota (2015) Kelly (2016) Hota (2017) 
Inclusion 
criteria 
Recurrence of CDI 
after at least one 
course of adequate 
antibiotic therapy, 
diarrhea for at least 
2 days, positive 
Meridian A/B toxin 
premier test* 
 Recurrence of CDI 
after at least one 
course of adequate 
antibiotic therapy, 
diarrhea for at least 
2 days, positive C. 
diff toxin test 
Outpatients with 3 or 
more documented CDI 
recurrences (defined as 
diarrhea for at least 2 
days + positive stool test 
– either ELISA or PCR- 
or evidence of 
pseudomembranous 
colitis) who did not 
maintain cure after a 
course of tapered or 
pulsed vancomycin (or 
equivalent) 
At least 2 episodes 
of laboratory or 
pathology 
confirmed CDI 
and had received 
at least one course 
of oral 
vancomycin , EIA 
or PCR accepted 
for lab 
confirmation 
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Exclusion 
criteria 
Immune 
compromise, recent 
chemo, HIV w/ CD4 
< 240, prednisone, 
pregnancy, use of 
antibiotics other 
than for C. difficile 
on day of inclusion, 
ICU, need for 
vasopressors 
Immune 
compromise due to 
chemotherapy, HIV, 
prolonged steroids, 
pregnancy, use of 
antibiotics other than 
vancomycin, 
metronidazole, or 
fidaxomicin at 
baseline, ICU 
admission, 
requirement of 
vasoactive drugs, 
other infectious 
causes of diarrhea 
Age >75, IBD, IBS, 
chronic diarrheal 
disorder, any immune 
compromise, 
anaphylactic food 
allergy, untreated in situ 
colorectal cancer 
Neutropenia, 
graft-vs-host dx, 
CDI requiring ICU 
admission, 
evidence of active 
severe colitis 
unresponsive to 
vancomycin, 
hypersensitivity or 
intolerance to oral 
vancomycin, 
chronic GI disease 
Pre-treatment 
FMT arm 
Vancomycin 500 mg 
QID PO for 4 days 
(stopped the day 
before FMT) + 
bowel lavage 
Vancomycin 125 mg 
QID PO for 3 
days** (stopped the 
day before FMT) + 
bowel prep 
At least 10 days of 
vancomycin therapy 
(stopped 2-3 days before 
procedure) + bowel prep 
Vancomycin 125 
mg QID for 14 
days 
Non-
FMT/control 
arm 
Vancomycin 500 mg 
QID PO for 14 days 
Vancomycin 125 mg 
QID PO for 10 days, 
followed by 125-500 
mg/day every 2-3 
days for at least 3 
weeks 
At least 10 days of 
vancomycin therapy 
(stopped 2-3 days before 
procedure) + bowel prep  
Vancomycin taper 
for 6 weeks: 125 
mg QID for 14 
days, then taper 
for 4 wks 
Retreatment 
allowed in 
FMT arm? 
No- 13/16 patients 
(81%) has resolution 
after first infusion, 3 
were retreated but 
were considered 
treatment failures in 
analysis 
Yes- PMC pts had 
infusions every 3 
days until resolution, 
also patients with 
relapse received 2nd 
infusion 
Unclear- Clinical failure 
pts un-blinded and 
offered open label FMT, 
unclear if these were 
included in ITT analysis 
No- Pts with 
recurrence offered 
crossover 
treatment, 
considered 
treatment failures 
in analysis 
Stool donors <60, volunteer 
hospital employees 
without patient 
contact, blood 
donors, or patient 
relatives 
<50, prefer relative 
or intimate 
Known or healthy 
volunteer 
Donors identified 
by recipients 
Donor 
exclusion 
criteria 
ID (infectious 
disease) risk, GI 
illness or complaint, 
family history of GI 
cancer or IBD, 
general illness, use 
of medications 
excreted in feces 
ID risk, antibiotics 
in 6 months, GI 
disease, IBD or GI 
cancer family 
history, systemic 
disease including 
diabetes or 
neurological 
disorder, use of 
medications 
excreted in feces 
ID risk, GI disease, 
features of metabolic 
syndrome, chronic pain 
condition, antibiotics in 
3 months 
ID risk, unclear 
what other criteria 
where used 
Stool 
preparation 
Fresh, transferred in 
plastic container to 
hospital immediately 
after donation, 
diluted in normal 
saline. 
Fresh (infused 
within 6 hours), 
diluted in normal 
saline 
Fresh, donors took 
osmotic laxative evening 
before donation, kept 
refrigerated or on ice 
before procedure, 
diluted in normal saline 
Fresh stool (no 
more than 48 
hours to 
procedure) 
dissolved in 
normal saline 
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Route of 
administration 
Nasoduodenal 
infusion 
Colonoscopy Colonoscopy Enema 
Treatment 
failure 
definition 
Diarrhea with 
positive C difficile 
toxin test 
Diarrhea for at least 
2 days, 
unexplainable by 
other causes, with or 
without positive 
stool toxin within 10 
weeks from the end 
of therapy 
Persistence or 
development of diarrhea 
and the need for 
additional anti-infective 
therapy for CDI with or 
without positive stool 
testing (PCR) for C. 
difficile 
 
Not clearly 
defined 
Primary end 
point 
Resolution of 
diarrhea associated 
with CDI w/o 
relapse after 10 
weeks 
Resolution of 
diarrhea associated 
with CDI 10 weeks 
after the end of 
treatment (follow up 
was extended for pts 
receiving >1 
infusion) 
 
Secondary endpoint: 
Toxin negative w/o 
recurrence at 5 and 
10 wks after end of 
treatment 
Resolution of diarrhea 
(i.e., fewer than three 
unformed stools for two 
consecutive days), with 
maintenance of 
resolution for the 
duration of the 8 week 
follow-up period and no 
further requirements for 
anti-infective therapy for 
C. difficile infection. 
Subjects who meet this 
definition will be 
considered cured 
regardless of results of 
follow-up stool testing 
for C. difficile 
 
Recurrence of 
symptomatic, 
laboratory-
confirmed CDI 
within 120 day f/u 
period; secondary 
outcomes included 
recurrence of CDI 
symptoms within 
14 and 120 days 
(not laboratory-
confirmed); 
recurrence of CDI 
within 120 days of 
crossover; days of 
diar- rhea in the 
120 days of 
follow-up; and 
CDI requiring 
hospital admission 
Follow up 
period 
10 weeks 10 weeks 8 weeks 120 days (16 
wks)- day 0 
considered day of 
FMT or first day 
of tapered vanco 
 
The first RCT, an open-label Dutch study published by van Nood et al. in 201329, 
enrolled 43 patients randomized to 3 treatment arms: short course vancomycin, bowel 
lavage, and FMT; full course vancomycin and bowel lavage; and full course vancomycin 
alone. Although the study planned to enroll 40 patients per treatment arm, it was 
terminated in interim analysis after 81% of the FMT treatment arm achieved the primary 
study outcome, no recurrence of CDI after 10 weeks, compared with 31% of the 
vancomycin alone group and 23% of the vancomycin plus bowel lavage group. As noted 
in their discussion, the vancomycin treatment arms experienced a considerably lower cure 
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rate than the 60% rate used in the power calculations for the study, which was based on 
the cure rate of vancomycin for first CDI episodes. Reasonable critiques of this study 
include unclear role of short course vancomycin in pre-treatment for the FMT group. An 
important limitation is a lack of stratified analysis (impossible post hoc because it would 
be underpowered) based on number of CDI recurrences, making it impossible to 
determine from the results of this study if FMT should be recommended for a first 
recurrence. 
 
The second RCT, also open-label, was conducted in Italy by Cammarota et al. and 
published in 2015. A total of 39 patients were randomized to receive either FMT via 
colonscopy after bowel lavage and a brief course of vancomycin, or a full vancomycin 
taper.  This study was similarly halted during interim analysis, as 90% of patients in the 
FMT group achieved durable resolution of CDI compared with only 26% in the 
vancomycin group27. Of note, the methodology for this study was amended after 
initiation. While the original study protocol planned to treat all subjects randomized to 
the FMT arm only once, it was altered such that patients in the FMT arm with 
pseudomembranous colitis were retreated every 3 days until resolution. This was done 
because the first 2 patients randomized to the FMT group both had pseudomembranous 
colitis, experienced relapses of CDI within 1 week of FMT, were switched to 
vancomycin, and ultimately died of sepsis. Both patients were considered FMT failures in 
terms of both the intention to treat and per protocol analyses. As a result of this protocol 
change, the 7 patients randomized to the FMT treatment arm that had pseudomembranous 
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received up to 4 infusions, with the ultimate result that 5 of them achieved a durable 
resolution of symptoms. Overall, 13/20 (65%) of patients in the FMT group achieved 
resolution of symptoms after 1 FMT treatment. However, as stated above, the overall 
success rate reported by the study was 90%, which includes patients with 
pseudomembranous colitis who were cured after re-treatment. This highlights an 
interesting inconsistency in the reporting of results in these types of trials; some studies 
report rate of cure from single FMT infusions and the results of repeat infusions on 
patients that failed the first infusion separately, while others, like this study, report the 
repeat infusion cure rate as the overall rate. Additionally, the disparate protocols that 
were adopted by this research group to address patients with pseudomembranous colitis 
versus those without speaks to a need for studies with larger sample sizes that would 
allow meaningful sub-group analyses, possibly leading to different FMT treatment 
protocols for different patients based on risk stratification.   
 
Kelly et al. performed a third randomized controlled trial in 2016 in the United States 
with the novel approach of comparing heterologous FMT to autologous FMT (FMT using 
the patient’s own feces) in order to allow blinding of participants and researchers with the 
autologous FMT group acting as a placebo group. The study included 46 subjects at 2 
academic medical centers who had experienced 3 or more episodes of CDI with the last 
recurrence treated with oral vancomycin; 90% of the heterologous FMT group achieved 
remission as measured by remission of CDI during an 8 week follow up, compared to 
62% of the autologous FMT group. All patients not cured by autologous FMT were 
   23
successfully cured with heterologous FMT33. Unlike the two prior trials, neither 
intervention involved treatment with antibiotics, however, all subjects entering the trial 
had treatment with at least 10 days of vancomycin that was continued until 2-3 days 
before the FMT procedure. Interestingly, the researchers reported a significant difference 
in response rate to autologous FMT between study sites, New York and Rhode Island, 
with around 90% of study participants in both the heterologous and autologous FMT 
groups achieving remission of symptoms at the New York site. The authors speculated 
that this may have been due to clinically different patients in New York, who had been on 
longer courses of vancomycin and had also taken more doses of fidaxomicin than the 
Rhode Island group. Overall, the Kelly study was the first double-blind trial with an 
attempt at a placebo control looking at FMT for recurrent CDI and it demonstrated a high 
rate of cure in the treatment arm compared with the placebo arm that is consistent with 
other studies. However, it is not directly comparable to the two RCTs that preceded it 
because all patients in the study received a potentially curative course of vancomycin 
prior to FMT.  Thus, this study investigated if FMT can prevent further CDI recurrence 
after symptom resolution in response to a full course of vancomycin, not whether FMT 
alone can act as a treatment for recurrent CDI and prevent future recurrences. 
Furthermore, the across site differences observed in the study with respect to cure rate 
among autologous FMT raises questions as to why, in this group, autologous FMT was 
just as effective as heterologous FMT at achieving a durable CDI cure. Further research 
is needed to clarify if autologous FMT itself has some benefit in treating CDI and also to 
investigate a possible strong placebo effect among patients who receive a procedure 
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versus no procedure to treat their recurrent CDI.  
 
Lastly, a 2017 open-label study in Canada by Hota et al, compared 14 days of 
vancomycin followed by FMT enema to vancomycin taper. The study was ended early 
once 30 patients had been randomized after a positive futility analysis; at the time of 
termination, results were equivocal, with 56% of the FMT group and 42% of the 
vancomycin taper group experiencing relapse during the follow up period of 120 days34. 
In their discussion, Hota et al stated that their results may be indicative that other studies 
have overestimated the efficacy of a single FMT administration to treat recurrent CDI, 
and point out that none of the previous trials have used the standard of care vancomycin 
taper as a comparison group. Specifically, they noted that one study used a 2 week course 
of vancomycin (the Kelly et al study) and another used 10 days of vancomycin followed 
by 3 weeks of pulsed vancomycin (the Cammarota study) . The authors also note that 
several previous studies have not limited recruitment to ill patients in active CDI 
recurrence as they did in their study and that, as such, some of the patients in previous 
studies may in fact already have been cured by prior treatment at the time of enrollment. 
They acknowledge that route of administration may be a factor in success of FMT but 
note that no studies to date have demonstrated clear superiority of one method and defend 
the choice of enema as one that is practical and well tolerated for many patients.  
 
In summary, RCTs comparing FMT for recurrent CDI with standard treatments or 
placebo have been heterogeneous with respect to both methods and conclusions. Key 
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methodological differences between the studies discussed have been outlined in Table 2. 
Inclusion criteria varied regarding number of recurrences, ranging from any number of 
recurrences in the van Nood trial to 3 or more recurrences in the Kelly trial. 
Requirements for laboratory confirmation of CDI also varied, with some studies 
specifying need for positive toxin EIA test and others accepting either the EIA or the less 
specific PCR test. Degree of vancomycin pre-treatment prior to FMT was another 
important difference. Van Nood et al and Cammarota et al both took the approach of a 
short (3-4 day) vancomycin treatment prior to FMT (although the dosing in the Van Nood 
study was much higher), while the Kelly et al and Hota et al had vancomycin 
pretreatment requirements similar to potentially curative standard-of-care dosing for 
recurrent CDI. Follow up periods for establishing lack-of-relapse were also quite 
different, ranging from 8 to 16 weeks.  
Finally, it is important to note relevant questions that have not been addressed by any of 
the RCTs to date. ICU patients and those requiring vasoactive therapy to maintain a 
normal blood pressure have been excluded from all 4 of these studies, meaning that the 
efficacy of FMT to treat CDI in ICU patients, regardless of whether or not CDI was the 
reason for their admission to the ICU, is still unknown. Additionally, no studies have 
compared FMT with fidaxomicin, despite evidence that fidaxomicin has superior 
performance than vancomycin for preventing relapse.  
 
Randomized controlled trials comparing heterologous FMT to heterologous FMT  
Prior reviews have grouped randomized controlled trials that compare heterologous FMT 
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to heterologous FMT with randomized controlled trials that compare heterologous FMT 
with vancomycin alone or to autologous FMT16,37–39. However, as described above, only 
4 such trials have compared FMT with standard treatments for recurrent CDI or placebo. 
The remaining trials have examined permutations of FMT protocols, including route of 
administration, fresh versus frozen stool, and alternative stool formulations, namely 
capsules. While these studies are important contributions to questions around how best to 
optimize FMT protocols, they are no more appropriate than the previously reviewed case 
series literature for elucidating the true efficacy of FMT since they have no non-FMT 
control group.  
 
Literature review (protocol described in “Randomized controlled trials comparing 
heterologous FMT to antibiotics or autologous FMT” section) revealed 4 published 
manuscripts31,32,40,41 that fall into the FMT to FMT comparison category. Youngster et al. 
performed a feasibility study in which 20 subjects with recurrent CDI were randomized 
to receive frozen inoculum FMT via colonoscopy or nasogastric tube (NGT). The 
combined response rate to first FMT in both groups in this study was 70% and a total 
response rate of 90% achieved after retreating subjects who relapsed after the first 
infusion. The success rate in the colonoscopy and NGT groups was not significantly 
different. The researchers in the study collected data on daily number of stools and 
subject-reported wellness before and after the procedure and found a significant decrease 
in stool number and increase in reported wellness the day after FMT compared with the 
day prior32.  
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In the largest randomized trial examining FMT for recurrent CDI to date, Lee et al. 
published a 2016 non-inferiority trial in which 232 subjects across 6 academic medical 
centers in Canada were randomized to receive fresh or frozen stool via enema. In this 
trial, 83% of the frozen FMT group and 85% of the fresh FMT group achieved clinical 
resolution (measured as at least 13 weeks free of recurrence of CDI after up to 2 FMT 
infusions). The authors concluded that frozen stool is non-inferior to fresh stool for FMT 
and is, therefore, a reasonable clinical option.  
 
More recently, Jiang et al. compared administration of fresh, frozen, and lyophilized stool 
by colonoscopy; 72 subjects who had experienced at least 3 occurrences of CDI were 
randomized to the 3 groups, and underwent microbiome analysis pre- and at regular 
intervals up to 30 days post-FMT. Clinical cure in this study was considered to be 
absence of CDI relapse after 2 months. All of the subjects in the fresh stool group and 
78% of the patients in the lyophilized group achieved cure, a difference that was 
significant. The frozen stool group had a cure rate intermediate between the others, which 
was not significantly different from either the fresh or lyophilized groups. All groups, 
including the lyophilized stool group, had reconstitution of microbial diversity at 30 
days41.  
 
All of these studies examined the viability of frozen stool for FMT in some way and none 
found it to be inferior to fresh. The interest in frozen stool is a matter of practicality and 
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convenience; it is far easier to freeze banked stool and use when needed than to obtain 
fresh stool from a qualified donor directly prior to every FMT performed. For similar 
reasons, there is interest in capsule based formulations, as these would simplify the 
procedure and make it accessible to more patients. Several groups have looked at capsule 
administration of stool products. In 2017, Kao et al. published a 3 site non-inferiority trial 
that randomized 116 recurrent CDI patients to receive FMT via capsule or colonoscopy. 
Donated stool for both preparations was frozen and thawed prior to administration. Cure 
rates, measured at 12 weeks, were 96% in both groups, demonstrating non-inferiority of 
capsules to colonoscopy40. The researchers also noted a higher tolerability among patients 
randomized to capsule delivery. Additionally, Youngster et al. published a 2014 trial in 
which 20 subjects with recurrent CDI received FMT via capsules of frozen stool with a 
first treatment efficacy rate of 70% and a retreatment efficacy rate of 90%30; this was an 
open label feasibility study and no control group was used.  
 
Overall, studies comparing one method of FMT to another to date have demonstrated 
non-inferiority of frozen stool products to fresh products for FMT, as well as non-
inferiority of capsule administration to colonoscopy. While a recent meta-analysis did 
find that lower GI delivery had significantly higher success rates than upper GI delivery 
(95% cure versus 88%)37, this analysis was largely based on uncontrolled case series.  
 
Systematic reviews and meta analyses  
Given the dominance of uncontrolled case series in the literature and the significant 
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variability that exists in the small number of randomized trials that have been conducted, 
it could be argued that meta-analysis of the data as they exist presently would be 
premature. At the same time, there is a pressing need for better therapies to treat recurrent 
CDI that minimize the probability of future relapses, so pooled effects estimates that are 
useful in guiding clinical decision-making are desirable. As discussed previously, 
Quraishi et al performed a meta-analysis in 2017 that combined 30 of the larger case 
series studies with 7 RCTs (all described in the above sections, with the exception of the 
Hota et al study, which was not included). The impressive 92% cure rate found in this 
meta-analysis is likely an overestimate; it relies largely on non-randomized, uncontrolled 
studies, and also excludes the Hota et al RCT, in which the cure rate for FMT was only 
44%. Another meta-analysis looking at the case series studies was specifically targeted 
toward long-term follow up and, therefore, included 18 studies that followed patients for 
at least 90 days38. This meta-analysis found a similar primary cure rate as the Quraishi 
study, 91.2%. The authors also analyzed early and late recurrence rates and found them to 
be 2.7% and 1.7%, respectively. Unfortunately, they neglected to define these terms 
anywhere in their article.  
 
A 2017 Australian RCT-only meta-analysis analyzed data from 284 patients in trials 
where FMT had been compared with placebo and/or vancomycin treatment, and found 
FMT to be statistically significantly more effective, with a RR of 0.4142. Significant 
heterogeneity among these trials was also noted. The researchers also analyzed RCTs 
comparing different FMT modalities and found that frozen preparations were just as 
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efficacious as fresh. They did not comment on differences in mode of delivery.  
 
Apart from summarizing current research with pooled effects estimates, some meta-
analyses have examined adverse effects in FMT trials. Most studies have reported that 
adverse effects from FMT have been largely limited to minor abdominal pain, bloating, 
and diarrhea on the day of FMT27,29–34,40,41. A 2016 review specifically looking at adverse 
events in FMT found that 28% of CDI patients who underwent FMT (a total of 831 
patients) experienced at least one adverse event attributable to or probably attributable to 
FMT, most commonly abdominal discomfort. While Wang et al. reported that 9.2% of 
patients experienced a serious adverse event, including death, infection, and relapse of 
inflammatory bowel disease, the FMT procedure was determined to be responsible for 
very few of these serious adverse events35. For example, of 38 deaths that occurred in 
over 1000 patients, 35 were definitely unrelated to FMT. While the authors reported that 
adverse events were overall more common in upper GI FMT administrations, whereas 
serious adverse events were more common with lower GI routes, it is unclear if this 
relationship remains when only analyzing adverse events likely related to FMT. In 
general, it appears that serious adverse events attributable to FMT are quite rare, 
however, a high quality meta-analysis on this topic would doubtless be an important 
contribution.  
 
Characterization of adverse events related to FMT is also hampered by the fact that few, 
if any, studies of FMT have followed patients for long enough to characterize any long 
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term adverse events that may be related to the procedure. However, long term adverse 
effects are theoretically quite plausible. The human microbiome has been linked to a 
number of intestinal and extra-intestinal conditions, including inflammatory bowel 
disease, irritable bowel syndrome, metabolic syndrome, and depression. It is possible 
that, by transplanting the microbiome of a donor to a patient, that recipients’ risk for one 
or more of these diseases, or others that are currently unknown to be linked to the 
microbiome, will be altered. Some FMT trials have used donor screening criteria that 
excludes donors with, for example, a family history of inflammatory bowel disease or 
metabolic syndrome but universal donor screening criteria have yet to be agreed upon.  
 
Since the benefit of summarizing data on efficacy and risk across studies is largely to 
clarify clinical decision-making, it is illuminating to examine manuscripts organized 
around clinical decisions. In 2018, Allegretti et al. published a clinical primer for using 
FMT to treat CDI, drawing from papers published to date. They recommend, for 
example, a rigorous testing methodology (a high negative predictive value test such as 
toxin gene PCR followed by a confirmatory high positive predictive value test such as 
toxin EIA) to rule out other possible causes of diarrhea in patients being considered for 
the FMT procedure and cite convincing data to support this recommendation. Regarding 
indication for FMT, the authors echo the recommendations of a working group of leaders 
in the fields of infectious disease and gastroenterology, who recommend FMT for the 
second recurrence of mild-moderate CDI and for the first recurrence of severe CDI.  
When it comes to other decision points such as route of administration of FMT, however, 
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the recommendations are more speculative. The authors state a general conclusion that 
lower delivery routes are more effective than upper16, however, this is not supported by 
the studies that they cite. One study cited was a pilot RCT with a sample size of 20 that 
found upper and lower routes to be equivocal, and the other study was a meta-analysis 
published in 2013 that relied exclusively on uncontrolled case data to draw conclusions 
regarding the superiority of one route over another. This is an example of conclusions 
related to clinical decision-making that are not supported by a robust evidence base, and 
highlights the need for more high-quality studies. 
 
In response to this continued problem of insufficient high-quality data, some reviews 
have focused on characterizing data quality problem, and in describing barriers to much 
needed large, well-designed RCTs. A 2017 systematic review by Bafeta et al analyzed 
the methodological reporting of 85 published reports examining FMT for various 
indications (a majority were for CDI), and found that many failed to report 
methodological components that would be critical for reproducing the studies. For 
example, they found that 67% of the studies failed to report on amount of stool used, 
whether it was fresh or frozen, and the duration of stool conservation43. A recent editorial 
by Young discussed these results, reflecting on how poor reporting of methodological 
details in FMT studies makes the planning of future trials difficult and leads to 
uncertainty of clinical decision-making. Young also points to the fact that FMT does not 
fit well within the regulatory categories established by the Food and Drug 
Administration, citing an ongoing debate about if FMT should be regulated as a drug or 
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as a tissue44. Overall, Young endorses the idea that, while the current enthusiasm for 
FMT in the medical and scientific communities is appropriate, it needs to be tempered 
given the quality of the current evidence, and more high quality trials are needed to 
address myriad unanswered questions. 
 
Summary 
The current literature examining FMT for recurrent CDI is compelling but incomplete. A 
large majority of published trials have been uncontrolled case series, which do not 
contribute to a robust evidence base. Randomized controlled trials have studied small 
numbers of patients, have been highly methodologically heterogeneous, and have had 
disparate results. Few RCTs have been placebo-controlled. Among RCTs comparing one 
mode of FMT to another, frozen stool appears non-inferior to fresh stool, and upper 
delivery routes appear non-inferior to lower, however, more research is needed. Given 
the relatively small number of RCTs that have been published, systematic reviews and 
meta analyses have relied heavily in uncontrolled case series, which undermines the 
strength of their conclusions. Additionally, a majority of RCTs looking at FMT have 
failed to report adequately on methodological details. Experts in the field have noted that 
is is an important barrier to clearer understanding, and have called for better 
standardization of methodological reporting.  
 
Several additional large-scale RCTs are likely needed in order to clarify the level of 
efficacy of FMT compared with standard treatments for recurrent CDI and provide clear 
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guidance about indications, contraindications, and optimize FMT procedural details. 
Here, we propose a double blind, placebo controlled RCT designed to address some of 
the most important current questions in the field, including examining the efficacy of 
frozen, oral, capsules compared with standard treatments, and exploring if FMT should 
be indicated for first recurrences of CDI. 
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PROJECT METHODS 
Project Justification 
Although FMT appears to be a promising therapy for treating recurrent CDI, RCTs to 
date have yielded conflicting results and have exhibited high heterogeneity with respect 
to methodology. Only one trial has been a placebo controlled, double blind design, and 
no RCTs have included patients experiencing a first CDI relapse as a sufficiently 
powered sub-group. While debate continues as to the preparation and route of 
administration of FMT, there is preliminary evidence that FMT administered orally as 
frozen, acid-resistant capsules has a similar efficacy to other methodologies. There have 
been no RCTs to date comparing FMT by oral capsule to standard-of-care vancomycin 
regimens. As frozen oral capsules are among the easiest and lowest-risk forms of FMT to 
administer, they warrant more detailed investigation. Finally, only two RCTs to date have 
explored FMT without a full course of vancomycin immediately prior, however, the 
results of these trials and other uncontrolled trials suggest that FMT may be more 
effective than vancomycin at curing recurrent CDI, as well as preventing relapse. 
Therefore, we designed a randomized, double blind, placebo controlled trial with the goal 
of answering the following questions: 1) Is FMT administered orally as frozen capsules 
superior to 14 days of vancomycin for producing a durable cure in patients experiencing a 
first relapse of CDI?, 2) Is FMT administered orally as frozen capsules superior to 14 
days of vancomycin followed by 4 week vancomycin taper for producing a durable cure 
in patients experiencing a second or later relapse of CDI? 
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Project Design 
The project design will be two parallel randomized, double blind, controlled, superiority 
trials comparing the standard-of-care vancomycin regimen to FMT by oral, frozen 
capsule for the indication of recurrent CDI. The two RCTs will differ with respect to 
inclusion criteria: Trial 1 will enroll patients experiencing a first relapse of CDI, while 
Trial 2 will enroll patients experiencing a second or later relapse. In both RCTs, patients 
randomized to the intervention arm will receive FMT via acid-resistant capsules of frozen 
donor feces, followed by placebo that simulates a course of oral vancomycin . Patients 
randomized to the control arm of both trials will receive a placebo FMT capsule followed 
by a course of oral vancomycin indicated by current Infectious Disease Society of 
America (IDSA) guidelines for the type of CDI relapse the patient is experiencing (a 14 
day course for first relapse or a 14 day course followed by a 4 week taper for second or 
later relapse). The primary study outcome in both RCTs will be treatment failure at any 
time after induction of therapy and up to 12 weeks after completion of therapy. Upon 
entry into the study, patients who are not already inpatient will be admitted to the clinical 
trial unit for observation for 7 days or until remission of CDI symptoms and afterwards 
will be followed on an outpatient basis for the remainder of the follow-up period. Study 
participants will be contacted by phone and asked about medication compliance, 
antibiotic usage, stool habits/diarrhea recurrence, and adverse events on days 3, 7, 14, and 
28 after discharge from the hospital, and every 4 weeks thereafter until 12 weeks after the 
cessation of trial therapy. Microbiome analysis will be performed on patient stool prior to 
induction of treatment and at 7, 30, and 90 days.  
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Project Population and Sampling 
Prospective trial participants will be identified from patients of Boston Medical Center 
and its affiliate outpatient offices. During the period of enrollment for the trials, all 
positive C. difficile stool tests from this patient population will automatically have 
confirmatory toxin EIA testing performed at the laboratory using the same stool sample. 
Trial staff will follow up on all positive toxin EIA  results on a daily basis by visiting or 
calling patient and performing chart review (see Figure 1). If prospective participants are 
found to meet all inclusion criteria and no exclusion criteria and provide informed 
consent, they will then be assigned to Trial 1 if they have been established to be 
experiencing a first recurrence of CDI and Trial 2 if they are experiencing a second or 
later recurrence.  
 
Inclusion criteria for both trials will be adults with a documented history of at least one 
episode of CDI treated in the past 8 weeks with an adequate course of an anti-CDI 
antibiotic (see Table 1) with subsequent resolution of diarrhea. Participants must meet 
clinical criteria for CDI at the time of enrollment, namely diarrhea by definition with a 
positive stool C. difficile toxin EIA.  Additionally, participants can have received a 
maximum of 3 days of anti-CDI antibiotics for the present CDI episode, as the study aims 
necessitate the exclusion of patients who might have remission of CDI symptoms 
attributable to antibiotics received before FMT. The requirement that study personnel 
initiate screening of patients within 24 hours of positive EIA should ensure that most 
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patients do not receive more than 3 days of anti-CDI antibiotics prior to enrollment. Once 
general inclusion and exclusion criteria are met, patients will be enrolled in Trial 1 or 
Trial 2 based on number of previous recurrences (see Figure 1). Key exclusion criteria 
include any immune compromise (including pregnancy) or conditions for which a risk of 
transient bacteremia would be concerning (mechanical heart valves), clinical instability 
(ICU admission), and GI pathology. For a full description of inclusion and exclusion 
criteria, see Table 3.  
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 Figure 1: Population Sampling and Enrollment Flow Chart 
 
 
 
 
Patients with any positive C. difficile stool test as detected by active lab surveillance of BMC 
inpatient and outpatient population 
During study enrollment period, all positive C. difficile stool tests performed at BMC are 
automatically triggered to have confirmatory toxin EIA as soon as first test is resulted 
(unless first positive test is a toxin EIA) 
EIA positive 
EIA 
negative 
Exclude from study 
Within 24 hours of positive toxin EIA, study personnel perform chart review and visit patient 
at bedside (if inpatient) or call (if outpatient) to establish: Has the patient had a previous 
episode of CDI that was treated within with last 8 weeks? 
Yes 
No 
Exclude from study 
Continue with remaining screening for inclusion/exclusion criteria, including diarrhea by 
definition, previously treated with full course of anti-CDI antibiotics with subsequent 
resolution of diarrhea. Does patient meet all criteria? 
Yes No 
Exclude from study 
Has the patient had at least one other episode of CDI (occurring before the previously 
identified episode that was treated within the last 8 weeks) that was treated within 16 
weeks of the present day?  
Yes No 
Consent and enroll 
in Trial 1 
Consent and enroll 
in Trial 2 
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Table 3: Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
Adult (age at least 18 years) 
Previous occurrence of CDI treated with an 
adequate course of metronidazole, 
vancomycin, or fidaxomicin where treatment 
ended within the past 8 weeks  
Diarrhea for at least 2 days (at least 3 
unformed stools per day or at least 8 
unformed stools in the last 48 hours)  
Positive stool test for C. difficile toxin A or B 
by EIA associated with current diarrheal 
illness  
Have received no more than 3 days of 
antibiotics to treat current episode of CDI 
Life expectancy < 3 months 
Immune suppressed status including HIV with 
CD4 count <500 
Currently undergoing chemotherapy  
Long term use of steroids 
Neutropenia 
Current admission to ICU for any indication 
Currently requiring vasoactive therapy to 
maintain adequate blood pressure 
Current requirement of antibiotics other than 
to treat CDI  
Previous FMT  
Previous participation in Trial 1 of this study 
(if being considered for Trial 2) 
Plan to undergo chemotherapy within 6 
months Pregnancy 
Irritable bowel syndrome 
Inflammatory bowel disease 
Untreated colorectal cancer 
Delayed gastric emptying, gastroparesis, or 
gastritis 
History of infective endocarditis 
Mechanical or prosthetic heart valve 
Mechanical joint 
Food allergy with a reaction of anaphylaxis 
Clinical evidence of ileus or toxic mega colon 
 
Sample size calculation: For Trial 1, we will conservatively assume a vancomycin 
treatment failure rate of 12% among patients with a first recurrence of CDI (the published 
range is 12-20%4). A reduction in treatment failure by 50% or more will be required to 
demonstrate clinical superiority. A two group chi square test with a 0.050 two-sided 
significance level will have 80% power to detect the difference between the vancomycin 
treatment group failure proportion of 0.12 and the FMT treatment group failure 
proportion of 0.06 (odds ratio of 0.468) when the sample size in each group is 356 
(sample size calculation completed with nQuery Advisor version 7.0, 2007). We have 
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chosen to use the most conservative estimation of vancomycin treatment failure rate in 
order to ensure adequate sample size. The risk of vancomycin failure is much smaller for 
first CDI recurrences than for later recurrences, so providers and their patients are likely 
to find them acceptable. As such, we predict that a relatively large difference in treatment 
failure rate between FMT and vancomycin would be necessary to change clinical 
recommendations in favor for FMT for first recurrences, which is why we have chosen a 
50% reduction in treatment failure as a threshold for clinical superiority. If we observe 
the low end of the vancomycin treatment failure range in our population, 12%, this will 
mean that we need to demonstrate an FMT treatment failure rate of 6% or less to show 
clinical superiority. We believe this is reasonable given that Kao et al observed a 96.2% 
cure rate in the capsule arm of their RCT that compared frozen capsules to colonoscopy 
as FMT delivery methods40.  
 
For Trial 2, we will conservatively assume a vancomycin treatment failure rate of 50% 
among patients with a second or later recurrence of CDI (the published range is 50-65% 
for second and later recurrences4). A reduction in treatment failure by 40% or more will 
be required to demonstrate clinical superiority. A two group chi square test with a 0.050 
two-sided significance level will have 80% power to detect the difference between the 
vancomycin treatment group failure proportion of 0.50 and the FMT treatment group 
failure proportion of 0.30 (odds ratio of 0.429) when the sample size in each group is 93 
(sample size calculation completed with nQuery Advisor version 7.0, 2007).  We have 
reduced the percent reduction in treatment failure to reach clinical superiority for Trial 2 
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because the failure rate for vancomycin among this cohort is predicted to be high, so a 
smaller percentage different still translates to a large clinical difference. Still, a 40% 
difference in treatment failure is very robust for showing clinical superiority, and in this 
case would mean that FMT treatment failure would need to be 20% or less if the 
vancomycin group experiences the minimum expected treatment failure rate of 50%. This 
is reasonable, as a majority of RCTs studying FMT to date, including those that have 
looked specifically at frozen capsule FMT, have achieved a cure rate of 80% or more27,29–
32,37,40.  
 
Although the target sample size per group for Trial 1 is nearly 4 times the target sample 
size for trial 2, we expect to recruit a great number of patients for Trial 1 than for Trial 2, 
given that prospective participants for Trial 2 are necessarily a subset of those who have 
had a single FMT recurrence in the past. As a result, it is expected that Trial 1 will enroll 
participants at a faster rate than Trial 2, so the time course for the two parallel trials to 
enroll the required number of participants will be less disparate than it might appear when 
considering sample size alone. It is important to note that the exclusion criteria (Table 3) 
prohibit participation in both Trial 1 and 2. 
 
Randomization and Interventions 
Randomization will be completed by trial staff immediately following informed consent 
and appropriate categorization to either Trial 1 or Trial 2. After assignment to the 
appropriate trial, patients will be randomized in a 1:1 fashion to the intervention or 
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control arm. Randomization will be carried out using pre-generated blocks by an un-
blinded investigator. Patients and study providers will be blinded to the randomization 
status of each participant, and study medications will be prepared by an un-blinded 
investigator without contact with the study participants, and administered by a blinded 
study nurse. The same process will be used when patients are being discharged from the 
hospital after the observation period; outpatient study medications will be provided at 
bedside by a blinded trial nurse who will instruct the patient on how to properly take the 
medications (oral vancomycin or sham vancomycin) at home.  
 
FMT arms: Upon randomization to the FMT arm of either trial, patients will discontinue 
any antimicrobial CDI therapy they may have been taking (note that inclusion criteria 
specify they cannot have been on these antibiotics for more than three days to meet 
criteria for the trial). If the patient has been taking anti-motility agents such as 
loperamide, these should also be discontinued. FMT capsules will be prepared in advance 
using the method described by Youngster et al30, and containing stool obtained from 
OpenBiome, a Boston-based organization that screens healthy donors and banks stool 
using a rigorous process (screening criteria described elsewhere45), in which less then 3% 
of applicants are successful in becoming donors.  Following the methodology described 
utilized by Youngster et al, patients will be made NPO  (nothing by mouth) once enrolled 
and capsules will be removed from -80 C storage to thaw prior to administration. After 4 
hours, the patient will receive 15 thawed, acid-resistant capsules .They will remain NPO 
for an additional hour after they have ingested the capsules. This process will be repeated 
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12 hours after the initial administration, for a total of 30 capsules. Each capsule will 
contain approximately 1.5-2 grams of fecal matter, so the target dose per patient for all 30 
capsules will be 45-60 grams.  This oral capsulized FMT protocol is the same as the one 
described by Youngster et al30 and target dose is supported by a dose-finding study by 
Allegretti et al45. All patients in the FMT arms will also begin a course of sham 
vancomycin at the same time that they initiate the FMT therapy. Patients in Trial 1 will 
receive a total of 14 days of sham vancomycin, while patients in Trial 2 will receive 14 
days followed by a 4-week taper (described below, also see Table 1). 
 
Vancomycin arms: Upon randomization to the vancomycin arm of either trial, patients 
will undergo the same procedure described above but will receive sham enteric capsules 
(frozen and thawed) that do not contain any fecal material. At the same time, they will 
begin vancomycin 125 mg four times daily by mouth for 14 days. Patients in Trial 2 will 
continue to a vancomycin taper for another 4 weeks after the 14 days has been 
completed: 125 mg twice daily for 1 week, then 125 mg once daily for 1 week, then 125 
mg/day every 2 days for 1 week, then 125 mg/day every 3 days for 1 week. 
 
Project Variables and Measurement Tools 
The primary study outcome in both RCTs will be treatment failure at any time after 
induction of therapy and up to 12 weeks after completion of therapy. As previously 
described, patients will be monitored for the first 7 days of the trial on an inpatient basis, 
either on the hospital floor to which they were previously admitted or in the clinical trial 
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unit if they do not otherwise meet inpatient criteria. Thus, monitoring for treatment 
failure will be done in person by study personnel for the first 7 days. Thereafter, patients 
will be contacted by phone on days 3, 7, 14, and 28 after discharge from the hospital, and 
every 4 weeks until 12 weeks after the completion of therapy, and administered a 
standard survey that will ask about recurrence of diarrhea. Patients will also be instructed 
to contact both their primary care physician (PCP) and trial personnel should they 
experience a recurrence of diarrhea at any time during the follow up period. Treatment 
failure will be defined as either of the following:  
 
1) Early treatment failure: Lack of resolution of diarrhea on day 7 of therapy, 
where the first day of therapy is day 0. Specifically, this will be defined as 
diarrhea by definition for 2 consecutive days, where one of the days must be day 
7. This criterion will be met if the patient has 3 or more unformed stools on day 6 
and 7, OR 8 or more unformed stools on day 6 and 7 combined) OR receipt of 
antibiotics to treat CDI outside of trial-administered medications at any time 
between day 0 and day 7 of trial therapy.  
2) Late treatment failure: Diarrhea by definition for at least 2 consecutive days 
between day 8 of therapy and 12 weeks after the cessation of therapy AND a 
positive stool test for C. difficile toxin A or B by EIA, OR receipt of antibiotics to 
treat CDI outside of trial-administered medications at any time between day 8 of 
therapy and 12 weeks after cessation of therapy 
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Patients who are prescribed antibiotics not used for the treatment of CDI during the 
follow up period will be considered at high risk for relapse in sub-group analysis but will 
not be considered treatment failures unless they also meet the above definition. 
 
Secondary study outcomes will include: Pre- and post- FMT microbiome analyses to 
determine proportion of patients in FMT arms with successful microbial engraftment  
(microbial diversity and species profile of FMT recipient becomes statistically 
significantly more similar to donor) and to better elucidate timing of engraftment; 
proportion of patients meeting definitions for early and late treatment failure (as 
described above), adverse events and serious adverse events potentially related to FMT or 
treatment failure during the follow up period. 
Other data to be collected: Demographic information of subjects, contact information for 
follow up, number of CDI recurrences, previous CDI treatments (including dose and 
duration), other antimicrobial usage within previous 8 weeks, CDI disease severity, 
screening laboratory results, colonoscopy results related to current illness (if any). 
 
Recruitment 
As previously described, prospective participants will be identified through laboratory 
surveillance for positive C. difficile stool EIA results within BMC and its associated 
clinics, and patients will then be further screened by investigators. Investigators will 
contact the patient’s primary care team (if the prospective participant is an inpatient) or 
PCP (if they are an outpatient) to request to arrange to speak with the patient in order to 
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perform the screening, either at bedside or by phone.  
 
Data Collection  
Standardized electronic forms with appropriate skip patterns will be developed for the 
purposes of initial chart biopsy and for screening patients at bedside or by phone, in order 
to standardize the process of screening and allow study staff to make an informed on-the-
spot decision about enrolling the patient once informed consent is obtained. Electronic 
forms will be administered using tablets, which will be strictly password protected and 
which only appropriate study staff will be granted access. Once randomized, study 
subjects will be assigned a unique identification number that does not include protected 
health information (PHI), and data from the electronic form will be uploaded to a 
Microsoft Access database and merged with their unique identification number. A 
database matching unique identification numbers to patient identifiers and randomization 
status will be maintained separately by a single, un-blinded investigator. Ongoing study 
data, including relevant results from the inpatient observation period and follow up data 
from phone interviews and laboratory data after discharge will be maintained in the 
Microsoft Access database, which will be password protected. All follow up phone 
interviews will be conducted in a standardized manner using electronic forms and 
subsequently uploaded to the database. 
 
Analysis  
Demographic data will be periodically analyzed across groups to monitor for appropriate 
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ongoing randomization. Patients who meet criteria for early treatment failure (diarrhea 
does not resolve or recurs by day 7 of treatment) will be un-blinded and monitored in the 
clinical trial unit until resolution of diarrhea and offered cross-over therapy. Patients who 
meet criteria for late treatment failure will be un-blinded, offered cross-over therapy, and 
assessed for requirement of inpatient level of care. All such will be considered treatment 
failures in the intention to treat analysis. Analysis of the intervention groups will occur 
once the computed sample sizes have been achieved and the main study database has 
been cleaned and locked. An intention-to-treat analysis will be carried out to estimate the 
treatment failure rate of FMT by oral, frozen capsule compared with standard-of-care 
vancomycin regimens for the treatment of CDI without recurrence for 12 weeks. We will 
use a two group chi square test with a 0.050 two-sided significance level to detect a 
difference in proportions of treatment failure among the FMT and vancomycin groups in 
each trial. Planned sub-group analyses include stratification of treatment failure 
categories into early and late to compare, for example, the proportion of early treatment 
failure in the FMT groups versus the vancomycin groups. A separate analysis of pre- and 
post- FMT microbiome species and diversity will also be carried out.  
 
Timeline and Resources 
Personnel: Principal investigator, 2-3 co-investigators (must be prescribing providers), 1 
RN, statistician, data system consultant to build and maintain MS Access database and 
electronic forms, 2 research assistants (1 for data entry and performing patient follow up 
interviews, 1 un-blinded to perform randomizations), 1 pharmacist (to prepare correct 
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placebo and live agent medications for administration by blinded study RN) ,laboratory 
technician to oversee creation and storage of stool enteric capsules, stool bank partner to 
provide donor stool, statistician, study coordinator. 
 
Pre-enrollment phase (most staff part time, coordinator, and data system consultant are 
full time): Train study personnel, set up laboratory surveillance network with Boston 
Medical Center (for example, a report within Epic that flags all positive C. diff tests), 
work with data system consultant to build databases and forms, make initial batch of 
enteric capsules (shelf life 4 months), ensure access to appropriate placebo medications, 
finalize study protocols with sufficient detail. Estimated time needed for this phase is 6 
months, including time needed for IRB approval. 
 
Enrollment phase (most staff full time, data system consultant, statistician are part time): 
Trial 1 and Trial 2 will proceed in parallel, estimated time to enroll the requisite number 
of participants is 2 years. If enrollment does not appear to be sufficient to meet this goal 
after 6 months, will seek to expand the study to other suitable sites within the greater 
Boston area. 
 
Post enrollment phase (most staff part time): Complete follow up for all patients still in 
the follow up period (may extend up to 18 weeks after the end of the enrollment period). 
Data cleaning and analysis. Estimated time for this phase is 5 months. 
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Resources: Tablets, computers with Epic access, phones, MS office, statistical analysis 
software (e.g. SAS, Stata, R), office space, laboratory space with freezer for long term 
storage of stool capsules, access to stool from a stool bank, beds on clinical research unit 
for use during patient observation periods. 
 
Institutional review board  
This study will be submitted to the IRB for full board review, as it involves intervening in 
the care provided to patients of BMC and extensive clinical contact between subjects and 
investigators. A substantial body of research exists supporting FMT as a safe and 
effective treatment for recurrent CDI, with oral enteric capsules being among the safest 
delivery methods currently available. While preliminary studies have been promising, 
oral enteric capsules have not been tested in a randomized double-blind trial against 
standard-of-care vancomycin, which has a high failure rate, particularly among patients 
with a history of more than one CDI recurrence. It is important FMT by oral enteric 
capsule be studied in the rigorous fashion proposed here in order to demonstrate a 
potential clinically significantly better efficacy for curing recurrent CDI and preventing 
recurrence. Furthermore, studies to date have not clarified the optimal indication for FMT 
with respect to first CDI recurrence versus later recurrences. This study seeks to recruit 
an appropriate number of patients experiencing a first CDI recurrence to adequately 
power a comparison of treatment failure of FMT in this group compared with standard-
of-care vancomycin.  
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CONCLUSION 
Discussion 
The choice to use frozen, capsulized, banked stool as the method of FMT delivery in the 
proposed RCTs is based on high-quality studies that have demonstrated the non-
inferiority of this method compared with FMT delivered by colonoscopy, combined with 
practical advantages offered by this method. These advantages include obviation of risks 
associated with upper endoscopy and colonoscopy, and lack of need for specialty 
providers, such as gastroenterologists, to perform the FMT procedure. Therefore, this 
choice of FMT method should not be considered a limitation of the study. Potential 
barriers to carrying out this study include that the RCTs proposed involve deviating from 
the standard-of-care treatment for recurrent CDI for patients randomized to the FMT 
arms of trials, since the decision has been made not to pre-treat with vancomycin prior to 
FMT. While this protocol may lessen the chance of securing IRB approval, we argue that 
several published RCTs support the idea that FMT alone may be curative, and that this 
warrants rigorous investigation so as to avoid exposing FMT candidates to unnecessary 
courses of antibiotics in the future. As a result of the proposed deviation from the 
standard-of-care and in order to ensure the safety of the patients we enroll, the study 
protocol calls for the observation of all participants in the clinical trial unit for the first 7 
days of treatment, unless they are already hospitalized. This requirement is likely to 
decrease the rate of informed consent among prospective participants. Finally, it is 
anticipated that showing a benefit of FMT over vancomycin treatment for a first CDI 
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recurrence will require a substantially larger sample size than showing a similar benefit 
for a second or later recurrence, owing to the much worse performance of vancomycin in 
preventing recurrence in the latter group. As such, Trial 1 may prove to be less feasible 
than Trial 2. Despite this, there is a clear need for RCTs that include first CDI recurrences 
as an adequately powered group, in order to clarify indications for FMT in recurrent CDI 
in the future.  
 
Summary and significance  
FMT as a treatment for recurrent CDI has shown impressive efficacy in many 
uncontrolled case series when compared with published vancomycin efficacy rates and 
has performed similarly well in a few, small RCTs comparing FMT to vancomycin 
and/or placebo. This has led many authors to the premature conclusion that FMT has 
been definitively established to be an evidenced-based treatment option for recurrent 
CDI. While excitement about FMT as a potentially very efficacious and safe therapy for 
recurrent CDI is warranted, it must be tempered with appropriate scientific caution. This 
is particularly true given the marked heterogeneity in methodology of the RCTs 
published to date and the over-reliance on uncontrolled case series by systematic reviews 
and meta-analyses. Although they will be subject to the unique regulatory difficulties that 
affect FMT studies, large, high-quality RCTs should continue, and investigators running 
these trials should be cognizant of the need for rigorous methodological reporting as 
demonstrated by Bafeta and colleagues. The project proposed here is designed to meet 
criteria for methodological rigor and to address several important outstanding questions, 
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including efficacy of FMT for first CDI recurrences and comparison of frozen, oral, 
capsulized FMT with standard antibiotic regimens. If shown to be efficacious in a large 
RCT, oral capsulized FMT alone as treatment for recurrent CDI has the potential to 
expand the number of patients with access to the FMT procedure substantially, decrease 
the use of unnecessary antibiotics in the treatment of recurrent CDI, and prevent 
thousands of recurrences per year in the United States.   
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